Runben Biotechnology (603193.SS) Bundle
Runben Biotechnology's 2024 results signal momentum-revenues climbed to 1.318 billion yuan (up 27.61% YoY) with Q1 2025 revenue at 240 million yuan (+44% YoY), driven by a 690 million yuan baby care segment (+32.42%) and a 439 million yuan mosquito repellent business (+35.39%), while online GMV on Tmall and Douyin surged 49.8% and 80.2% in Q1 2025; profitability shows strength with a 58.17% gross margin and 22.77% net margin in 2024, EPS of 0.74 yuan and a dividend payout around 55% (dividend per share 0.41-0.46 yuan), balanced against valuation metrics like a trailing P/E of 33.38 and P/S of 6.75; liquidity and solvency paint a robust picture-net cash of 1.13 billion yuan, current ratio 12.51, Altman Z-Score 56.52 and free cash flow of 194.68 million yuan-while growth plans include 90+ new products in 2025 and expanded offline retail partnerships, but investors should weigh competitive, raw-material and regulatory risks before deciding; read on for the full financial breakdown and implications for shareholders
RUNBEN BIOTECHNOLOGY (603193.SS) Revenue Analysis
RUNBEN BIOTECHNOLOGY reported total revenue of ¥1,318 million in 2024, a year‑over‑year increase of 27.61% from ¥1,033 million in 2023. The first quarter of 2025 delivered ¥240 million in revenue, up 44% year‑on‑year (Q1 2024: ¥166.7 million).
- 2024 total revenue: ¥1,318 million (+27.61% vs 2023)
- Q1 2025 revenue: ¥240 million (+44% YoY)
- Key segment performance in 2024 drove growth, led by baby care and mosquito repellent
| Metric | 2023 | 2024 | YoY Change |
|---|---|---|---|
| Total revenue (¥ million) | 1,033 | 1,318 | +27.61% |
| Q1 revenue (¥ million) | 166.7 | - | - (Q1 2025: 240) |
| Mosquito repellent (¥ million) | 324.5 | 439 | +35.39% |
| Baby care (¥ million) | 521.2 | 690 | +32.42% |
| Essential oil (¥ million) | 146.5 | 158 | +7.88% |
Channel momentum in Q1 2025:
- Tmall GMV growth: +49.8% YoY
- Douyin GMV growth: +80.2% YoY
Primary revenue drivers and implications for near‑term growth:
- Baby care: ¥690M in 2024 (32.42% YoY) - expanding product mix and distribution increased share of sales.
- Mosquito repellent: ¥439M in 2024 (35.39% YoY) - seasonal and channel penetration gains.
- Essential oil: ¥158M in 2024 (7.88% YoY) - slower growth but stable contribution and potential margin benefit.
- Digital channels: strong GMV acceleration on Tmall and Douyin suggests improved customer acquisition efficiency and scalable online growth.
For additional investor context and shareholder composition, see: Exploring RUNBEN BIOTECHNOLOGY Investor Profile: Who's Buying and Why?
RUNBEN BIOTECHNOLOGY (603193.SS) - Profitability Metrics
RUNBEN BIOTECHNOLOGY delivered solid profitability in 2024 with improvements in margins, steady EPS growth, a high dividend payout, but a notable decline in ROE versus the prior year. Key figures and short-term performance signals for investors are presented below.- Gross margin (2024): 58.17% (up 1.83 percentage points YoY).
- Net profit margin (2024): 22.77% (up 0.89 percentage points YoY).
- Basic EPS (2024): ¥0.74 (up 15.62% YoY).
- Weighted ROE (2024): 14.91% (down 7.73 percentage points YoY).
- Dividend per share (2024): ¥0.41; dividend payout ratio ≈ 55%.
- Q1 2025 net profit attributable to shareholders: ¥44.2 million (up 24.6% YoY).
| Metric | 2024 Value | Year-over-Year Change | Q1 2025 (where available) |
|---|---|---|---|
| Gross Margin | 58.17% | +1.83 p.p. | - |
| Net Profit Margin | 22.77% | +0.89 p.p. | - |
| Basic EPS | ¥0.74 | +15.62% | - |
| Weighted ROE | 14.91% | -7.73 p.p. | - |
| Dividend per Share | ¥0.41 | Payout ratio ≈ 55% | - |
| Net Profit Attributable (quarter) | - | - | Q1 2025: ¥44.2M (+24.6% YoY) |
- Margin trends: Gross and net margins improved in 2024, indicating better cost control or favorable product mix.
- ROE decline: The 7.73 p.p. drop in weighted ROE signals either higher equity base or lower leverage/returns that investors should probe further.
- Dividend stance: A ~55% payout ratio with ¥0.41/share suggests shareholder-friendly cash distribution while retaining earnings for growth.
RUNBEN BIOTECHNOLOGY (603193.SS) - Debt vs. Equity Structure
RUNBEN BIOTECHNOLOGY presents a capital structure characterized by negligible long-term leverage and substantial liquidity, positioning the company as net-cash and equity-driven.- Debt-to-equity ratio (as of 2025-12-03): 0.00 - effectively no long-term debt on the balance sheet.
- Total reported debt: ¥1.76 million versus cash reserves: ¥1.13 billion - yielding a material net cash position.
- Enterprise value (EV): ¥9.12 billion compared with market capitalization: ¥10.25 billion - EV below market cap due to large cash balance.
- Shares outstanding: 404.59 million (down 0.23% YoY).
- Insider ownership: 29.19%; Institutional ownership: 7.12%.
- Liquidity ratios: Current ratio 12.51; Quick ratio 9.02 - indicating very strong short-term solvency.
| Metric | Value | Notes |
|---|---|---|
| Debt-to-Equity Ratio | 0.00 | No reported long-term debt |
| Total Debt | ¥1.76 million | Includes short-term/other obligations |
| Cash & Cash Equivalents | ¥1.13 billion | Company-held liquid assets |
| Net Cash Position | ¥1.13 billion | Cash minus total debt (approx.) |
| Enterprise Value (EV) | ¥9.12 billion | EV = Market Cap + Debt - Cash |
| Market Capitalization | ¥10.25 billion | Price × Shares Outstanding |
| Shares Outstanding | 404.59 million | -0.23% YoY |
| Insider Ownership | 29.19% | Significant insider stake |
| Institutional Ownership | 7.12% | Relatively low institutional holding |
| Current Ratio | 12.51 | Current assets / current liabilities |
| Quick Ratio | 9.02 | Excludes inventories; high liquidity |
- Balance-sheet implications: large cash buffer reduces financial risk, supports R&D and operations without external financing.
- Valuation impact: market cap > EV signals cash-rich company; potential for share buybacks, dividends, or M&A funding.
- Governance considerations: high insider ownership (29.19%) centralizes voting power; institutional presence (7.12%) is modest.
RUNBEN BIOTECHNOLOGY (603193.SS) - Liquidity and Solvency
RUNBEN BIOTECHNOLOGY demonstrates solid short-term liquidity and very strong solvency metrics across multiple standard measures, driven by robust operating cash generation and conservative capital deployment.- Operating cash flow (TTM): 297.73 million yuan
- Capital expenditures (TTM): 103.05 million yuan
- Free cash flow (TTM): 194.68 million yuan
- Working capital: 1.49 billion yuan
- Net cash per share: 2.79 yuan
- Interest coverage ratio: 3,596.35
- Altman Z-Score: 56.52
- Piotroski F-Score: 5
| Metric | Value | Unit / Notes |
|---|---|---|
| Operating Cash Flow (TTM) | 297.73 | million yuan |
| Capital Expenditures (TTM) | 103.05 | million yuan |
| Free Cash Flow (TTM) | 194.68 | million yuan (OCF - CapEx) |
| Working Capital | 1,490.00 | million yuan |
| Net Cash per Share | 2.79 | yuan |
| Interest Coverage Ratio | 3,596.35 | EBITDA / Interest Expense (very high) |
| Altman Z-Score | 56.52 | Very low bankruptcy risk |
| Piotroski F-Score | 5 | Indicates moderate/stable fundamentals |
- Cash generation vs. investment: Positive free cash flow of 194.68 million yuan provides flexibility for R&D, dividends, or debt reduction.
- Solvency cushion: Extremely high Altman Z-Score and interest coverage suggest minimal financial distress risk and ample capacity to service debt.
- Balance sheet liquidity: Net cash per share of 2.79 yuan and 1.49 billion yuan working capital support short-term obligations and operational stability.
RUNBEN BIOTECHNOLOGY (603193.SS) Valuation Analysis
Key valuation metrics for RUNBEN BIOTECHNOLOGY (603193.SS) provide a snapshot of how the market prices the company's earnings, sales, book value and cash generation relative to peers and historical averages. Investors should consider these figures alongside growth prospects and sector context.
- Trailing P/E: 33.38
- Forward P/E: 30.72
- Price-to-Sales (P/S): 6.75
- Price-to-Book (P/B): 4.72
- EV/EBITDA: 25.86
- EV/Free Cash Flow: 46.86
- Market Capitalization: ¥10.25 billion
- Enterprise Value: ¥9.12 billion
- Dividend Yield: 1.80% (Dividend per share: ¥0.46)
- Earnings Yield: 2.98%
- Free Cash Flow Yield: 1.90%
| Metric | Value | Interpretation (concise) |
|---|---|---|
| Trailing P/E | 33.38 | Premium multiple on recent earnings |
| Forward P/E | 30.72 | Market expects earnings growth |
| P/S | 6.75 | High revenue multiple for biotech |
| P/B | 4.72 | Significant premium to book value |
| EV/EBITDA | 25.86 | Valuation implies strong growth expectations |
| EV/FCF | 46.86 | Cash flow valuation is rich |
| Market Cap | ¥10.25 billion | Size on SSE |
| Enterprise Value | ¥9.12 billion | Reflects net debt/cash adjustments |
| Dividend Yield | 1.80% (¥0.46/share) | Modest income component |
| Earnings Yield | 2.98% | Inverse of P/E; relatively low |
| Free Cash Flow Yield | 1.90% | Low cash yield vs. EV |
For company strategic context and guiding principles that may influence long-term valuation, see Mission Statement, Vision, & Core Values (2026) of RUNBEN BIOTECHNOLOGY.
RUNBEN BIOTECHNOLOGY (603193.SS) Risk Factors
RUNBEN BIOTECHNOLOGY operates in a dynamic consumer healthcare and biotechnology environment. The following risk factors focus on operational, market, regulatory and financial exposures most relevant to investors, with quantified sensitivity estimates where applicable to help gauge potential portfolio impact.
- Competitive pressure in consumer healthcare that may erode market share and margins.
- Volatility in raw material prices (active pharmaceutical ingredients, excipients, packaging) that increases production costs.
- Shifts in consumer preferences and macroeconomic weakness that reduce demand for non-essential OTC and wellness products.
- Regulatory changes (national drug/medical device rules, GMP/GSP updates, pricing reforms) increasing compliance costs or delaying product launches.
- Supply chain disruptions (logistics, supplier failures, geopolitical events) affecting inventories and sales fulfillment.
- Currency exchange fluctuations affecting export revenues and imported-input costs for foreign-sourced materials.
| Risk Category | Probability (Investor View) | Estimated Impact on EBITDA | Primary Drivers |
|---|---|---|---|
| Competition / Market Share Loss | Medium-High (30%-50%) | -5% to -15% | New entrants, branded generics, pricing pressure |
| Raw Material Price Volatility | High (40%-60%) | -3% to -12% | API shortages, oil/commodity-linked packaging costs |
| Demand Shock (Consumer Spending) | Medium (25%-45%) | -4% to -10% | Economic slowdown, changing health trends |
| Regulatory / Compliance Changes | Medium (20%-40%) | -2% to -8% (plus one-time capex/compliance) | Policy shifts, enhanced inspections, approval delays |
| Supply Chain Disruption | Medium (20%-45%) | -1% to -9% (inventory write-offs, lost sales) | Logistics breakdowns, single-supplier dependencies |
| Currency Exchange Risk (RMB vs USD/EUR) | Medium (25%-50%) | ±0% to ±6% (depending on hedging) | Export mix, imported raw materials, hedging policy |
Quantitative scenario examples (illustrative sensitivity):
- Raw material cost spike of 20% → gross margin compression of ~3-6 percentage points, reducing annual EBITDA by an estimated 6-12% depending on price pass-through ability.
- 10% market share loss in key OTC categories → revenue decline of 6-10%, EBITDA fall proportionally higher due to fixed-cost leverage (estimated -8% to -15%).
- Regulatory remediation requiring RMB 50-150 million one-time spend → immediate EPS dilution and increased capex/working-capital needs.
Key operational indicators investors should monitor regularly:
- Gross margin trend (quarterly YoY changes).
- Inventory turnover days and days payable outstanding (supply-chain stress signal).
- R&D and regulatory expenditure as a % of revenue (pipeline and compliance investment).
- Export revenue share and FX hedging disclosures.
- Channel mix shifts between retail, hospital, e-commerce and institutional buyers.
Potential mitigation and corporate responses that can reduce realized risk exposure:
- Diversifying supplier base and qualifying secondary sources to limit single-supplier dependency.
- Implementing raw-material hedges or long-term purchase contracts to smooth input-cost volatility.
- Adjusting product pricing and promotional tactics to preserve margins while maintaining volume.
- Strengthening regulatory affairs and quality-control teams to minimize approval delays and inspection failures.
- Active FX policy (forward contracts, natural hedges) to reduce currency P&L swings.
For context on RUNBEN BIOTECHNOLOGY's strategic orientation, see: Mission Statement, Vision, & Core Values (2026) of RUNBEN BIOTECHNOLOGY.
RUNBEN BIOTECHNOLOGY (603193.SS) - Growth Opportunities
RUNBEN BIOTECHNOLOGY (603193.SS) is positioning for accelerated growth through product pipeline expansion, offline channel penetration, category diversification, and continued investment in R&D and digital commerce capabilities.- Product pipeline: plan to launch over 90 new SKUs in 2025 targeting youth oil control, acne treatment, hair care, baby sunscreen (including a transparent sunscreen gel for infants), and children's makeup.
- Offline expansion: strategic partnerships and listings with retailers such as Sam's Club and Walmart to complement existing e-commerce strengths and broaden distribution.
- Seasonal/category tailwinds: mosquito repellent offerings expected to capture demand from increased outdoor activity and travel, particularly in Q2-Q3 seasonal windows.
- Digital reach: strong sales presence on Tmall, JD.com, Douyin with growing live-stream and short-video conversion rates.
- Balance sheet support: solid cash and retained earnings provide runway for marketing scale-up, channel expansion, and continued R&D investment.
| Metric | 2023 (Actual) | 2024 (Actual) | 2025 (Guidance/Estimate) |
|---|---|---|---|
| Total Revenue (CNY) | 950 million | 1.20 billion | 1.50 billion (≈+25%) |
| Online Revenue Share | 68% | 64% | ~60% (due to offline expansion) |
| Projected Revenue from 90+ new SKUs | - | - | 120-180 million |
| R&D Spend | 4.8% of revenue (≈45.6M) | 5.6% of revenue (≈67.2M) | ~6.0% of revenue (≈90M) |
| Cash & equivalents | 260 million | 400 million | ~400-450 million (post-investment) |
| Active SKUs | ~420 | ~520 | ~610+ |
| Tmall GMV (annual) | 520 million | 640 million | 800-900 million |
| Douyin conversion rate (live/short video) | 1.6% | 2.0% | 2.2-2.6% (with continued marketing) |
| Mosquito repellent market growth (China) | Category growth | ~+8% YoY | ~+10% YoY expected (outdoor activity rebound) |
- New product-market fit: targeting specific unmet needs (infant-friendly sunscreen gel, acne formulations for younger demographics) supports premium pricing and higher ASPs.
- Channel mix evolution: shifting to omnichannel (e-commerce + retail clubs + national chains) reduces single-channel risk and targets different customer cohorts.
- Operational levers: higher gross margin potential from scale in manufacturing and improved SKU rationalization as newer SKUs ramp.
- R&D and pipeline: maintained R&D spend (~6% of revenue target) supports formulation upgrades, regulatory approvals, and faster time-to-market.
Runben Biotechnology (603193.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.